Shaw AT, Peters S, Mok T, et al. Alectinib versus crizotinib in treatment-naive advanced ALK-positive non-small cell lung cancer (NSCLC): Primary results of the global phase III ALEX study. J Clin Oncol 35, 2017 (suppl; abstr LBA9008).
ERBB-mutaties als biomarker voor uitkomst plaveiselcelcarcinoom van de long?
jan 2019 | Longoncologie